A summary of implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
Scott M
SM
Grundy
James I
JI
Cleeman
C Noel Bairey
CN
Merz
H Bryan
HB
Brewer
Luther T
LT
Clark
Donald B
DB
Hunninghake
Richard C
RC
Pasternak
Sidney C
SC
Smith
Neil J
NJ
Stone
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D008078:Cholesterol, LDL / Q000097:blood; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data*; D003327:Coronary Disease / Q000453:epidemiology / Q000517:prevention & control; D006040:Goals; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000188:drug therapy* / Q000453:epidemiology; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D012306:Risk; D014280:Triglycerides / Q000097:blood
D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D014280:Triglycerides